Pathogenesis and progression of monoclonal gammopathy of undetermined significance

J Bladé1, L Rosiñol, M T Cibeira

  • 1Department of Hematology, Institut of Hematology and Oncology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain. jblade@clinic.ub.rs

Leukemia
|August 1, 2008
PubMed

Insights

Monoclonal gammopathy of undetermined significance (MGUS) affects 3% of adults over 50. While risk of progression to multiple myeloma (MM) is similar across races, certain factors predict transformation, necessitating annual monitoring for high-risk individuals.

Area of Science:

  • Hematology
  • Oncology
  • Epidemiology

Background:

  • Monoclonal gammopathy of undetermined significance (MGUS) is common in older adults, with higher prevalence in Black individuals compared to Caucasians.
  • The risk of progression from MGUS to multiple myeloma (MM) is comparable between racial groups.
  • Understanding MGUS progression is crucial for early detection and management of multiple myeloma.

Purpose of the Study:

  • To summarize the epidemiology and progression of MGUS.
  • To identify predictors of malignant transformation from MGUS to MM.
  • To recommend appropriate monitoring strategies for MGUS patients.

Main Methods:

  • Literature review and synthesis of epidemiological data on MGUS prevalence and incidence.
  • Analysis of factors associated with progression from MGUS to MM.
  • Review of clinical guidelines for MGUS patient management.

Main Results:

  • MGUS prevalence increases with age, reaching 3% in Caucasians over 50.
  • Black individuals exhibit higher prevalence rates of MGUS and MM compared to whites.
  • Key predictors of malignant transformation include plasma cell burden, IgA isotype, and specific plasma cell ratios.

Conclusions:

  • Annual monitoring of MGUS patients, especially those at high risk, is recommended to detect MM early.
  • Early detection of MM can prevent severe complications like renal failure and skeletal involvement.
  • Further research into the mechanisms of MGUS progression may improve therapeutic strategies.

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...